STADA founded the French sales company
EG Labo SAS - Laboratoires
Eurogenerics in Paris in 1996.
Sales in France were, with EUR 19.0 million in the first quarter of 2012 (1-3/2011: EUR 18.8 million), at approximately the same level as the corresponding period of the previous year.
In view of the still difficult framework conditions in the French market including, among other things, a high level of price competition, sales of French generics decreased by 4% to EUR 16.9 million (1-3/2011: EUR 17.7 million). Generics thus contributed 89% (1-3/2011: 94%) to STADA’s local sales.
Sales generated by STADA in France with branded products recorded a plus of 87% to EUR 2.1 million (1-3/2011: EUR 1.1 million), which was primarily attributable to the acquisition in the first quarter of 2012 of French Company LABORATOIRES D’ETUDES ET DE RECHERCHES EN OLIGO ELEMENTS THERAPHIE which has been consolidated in the Group since February 1, 2012. Branded products thus contributed 11% (1-3/2011: 6%) to STADA’s sales in France.
For financial year 2012, the Group expects more or less steady sales development in France with operating profitability which continues to be below Group average.
| 1) | Sales below EUR 0.05 million were rounded to EUR 0.0 million. |